fluconazole has been researched along with Disease Models, Animal in 181 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The emergence of fluconazole-resistant Cryptococcus gattii is a global concern, since this azole is the main antifungal used worldwide to treat patients with cryptococcosis." | 7.83 | Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis. ( César, IC; Costa, MC; Freitas, GJ; Holanda, RA; Paixão, TA; Pianetti, GA; Ramos, LH; Ribeiro, NQ; Santos, DA; Santos, JR, 2016) |
| " We used the neutropenic mice model of disseminated candidiasis to challenge the therapeutic equivalence of three generic products of fluconazole compared with the innovator in terms of concentration of the active pharmaceutical ingredient, analytical chemistry (liquid chromatography/mass spectrometry), in vitro susceptibility testing, single-dose serum pharmacokinetics in infected mice, and in vivo pharmacodynamics." | 7.81 | Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. ( Agudelo, M; Gonzalez, JM; Rodriguez, CA; Vesga, O; Zuluaga, AF, 2015) |
| "The efficacy of allicin compared with fluconazole in alleviating systemic Candida albicans infections was evaluated both in vitro and in vivo through a systemic candidiasis mouse model." | 7.77 | Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model. ( Alizadeh, F; Chong, PP; Harmal, NS; Jahromi, MA; Khodavandi, A; Ng, KP; Othman, F; Sekawi, Z; Sidik, SM, 2011) |
| "In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole." | 7.76 | Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. ( Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK, 2010) |
| " We evaluated the trailing effect of Candida isolates tested with itraconazole in a guinea pig model of systemic candidiasis." | 7.76 | Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. ( Chen, E; Leitz, GJ; Odabasi, Z; Ostrosky-Zeichner, L; Paetznick, VL; Rex, JH; Rodriguez, JR, 2010) |
| " The aim of the present study was to investigate the effects of ascorbic acid (AA) on the antifungal activity of fluconazole (FCZ) in a systemic murine candidiasis model as well as in vitro." | 7.75 | Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis. ( Cao, YB; Cao, YY; Gao, PH; Jia, JH; Jia, XM; Jiang, YY; Li, MB; Liao, WQ; Wang, Y, 2009) |
| "Subconjunctival administration of micafungin was effective in the treatment of experimental Candida keratitis." | 7.74 | Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits. ( Hiraoka, T; Kaji, Y; Nanbu, PN; Okamoto, F; Oshika, T; Wakabayashi, T, 2007) |
| "To investigate the relative pathogenicity of Candida albicans treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis." | 7.73 | Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. ( Duhamel, GE; Hoerrmann, N; Hornby, JM; Navarathna, DH; Nickerson, KW; Parkhurst, AM, 2005) |
| "Rats in Fp groups were given fluconazole in doses of 0 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg by gavage 30 min before induction of peritonitis." | 7.72 | Fluconazole attenuates lung injury and mortality in a rat peritonitis model. ( Arshaduddin, M; Evans, DP; Jacobs, S; Khan, HA; Moutaery, AA; Tariq, M, 2003) |
| "We determined the pharmacodynamic parameter and the magnitude of that parameter that was predictive of the efficacy of fluconazole in the treatment of disseminated candidiasis." | 7.70 | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. ( Andes, D; van Ogtrop, M, 1999) |
| "The time of initiation of fluconazole treatment with or without dexamethasone, and the impact on mycological outcome and drug pharmacokinetics were assessed in a murine model of disseminated cryptococcosis." | 7.70 | Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. ( Dromer, F; Dupont, B; Improvisi, L; Lortholary, O; Nicolas, M; Petitjean, O; Ronin, O; Soreda, S; Tod, M, 1999) |
| "The present studies were performed to determine whether any beneficial interaction results from combination therapy with recombinant human granulocyte colony-stimulating factor (GCSF) and fluconazole in disseminated candidiasis in mice." | 7.69 | Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. ( Bocanegra, R; Graybill, JR; Luther, M, 1995) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 7.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "The efficacy of fluconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis." | 7.68 | The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. ( Andriole, VT; George, D; Miniter, P; Patterson, TF, 1991) |
| "Cryptococcosis is a common opportunistic infection in patients with advanced HIV infection and may also affect immunocompetent patients." | 5.56 | Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis. ( da Silva de Bastiani, FWM; de Azevedo Melo, AS; de Castro Spadari, C; Ishida, K; Pisani, PBB, 2020) |
| "Cryptococcosis is an invasive infection caused by yeast-like fungus of the genera Cryptococcus spp." | 5.46 | A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression. ( Abrahão, JS; Barcellos, VA; Bretas Oliveira, D; Carneiro, HC; Fontes, AC; Oliveira, LV; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, NQ; Santos, DA; Santos, JR; Vainstein, MH, 2017) |
| " Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent." | 5.43 | The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( Bozó, A; Domán, M; Kardos, G; Kovács, R; Majoros, L; Varga, I, 2016) |
| "In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles." | 5.32 | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. ( Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003) |
| "Fluconazole alone was not found significantly effective against C." | 5.32 | Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 5.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| "The emergence of fluconazole-resistant Cryptococcus gattii is a global concern, since this azole is the main antifungal used worldwide to treat patients with cryptococcosis." | 3.83 | Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis. ( César, IC; Costa, MC; Freitas, GJ; Holanda, RA; Paixão, TA; Pianetti, GA; Ramos, LH; Ribeiro, NQ; Santos, DA; Santos, JR, 2016) |
| " Although polyploid titan cells generated haploid daughter cell progeny upon in vitro replication under nutrient-replete conditions, titan cells treated with the antifungal drug fluconazole produced fluconazole-resistant diploid and aneuploid daughter cells." | 3.81 | Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation. ( Berman, J; Fraser, JA; Fu, MS; Gerstein, AC; Li, Z; Mukaremera, L; Nielsen, K; Ormerod, KL, 2015) |
| " We used the neutropenic mice model of disseminated candidiasis to challenge the therapeutic equivalence of three generic products of fluconazole compared with the innovator in terms of concentration of the active pharmaceutical ingredient, analytical chemistry (liquid chromatography/mass spectrometry), in vitro susceptibility testing, single-dose serum pharmacokinetics in infected mice, and in vivo pharmacodynamics." | 3.81 | Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. ( Agudelo, M; Gonzalez, JM; Rodriguez, CA; Vesga, O; Zuluaga, AF, 2015) |
| "The efficacy of allicin compared with fluconazole in alleviating systemic Candida albicans infections was evaluated both in vitro and in vivo through a systemic candidiasis mouse model." | 3.77 | Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model. ( Alizadeh, F; Chong, PP; Harmal, NS; Jahromi, MA; Khodavandi, A; Ng, KP; Othman, F; Sekawi, Z; Sidik, SM, 2011) |
| " We evaluated the trailing effect of Candida isolates tested with itraconazole in a guinea pig model of systemic candidiasis." | 3.76 | Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. ( Chen, E; Leitz, GJ; Odabasi, Z; Ostrosky-Zeichner, L; Paetznick, VL; Rex, JH; Rodriguez, JR, 2010) |
| "In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole." | 3.76 | Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. ( Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK, 2010) |
| " The aim of the present study was to investigate the effects of ascorbic acid (AA) on the antifungal activity of fluconazole (FCZ) in a systemic murine candidiasis model as well as in vitro." | 3.75 | Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis. ( Cao, YB; Cao, YY; Gao, PH; Jia, JH; Jia, XM; Jiang, YY; Li, MB; Liao, WQ; Wang, Y, 2009) |
| "Subconjunctival administration of micafungin was effective in the treatment of experimental Candida keratitis." | 3.74 | Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits. ( Hiraoka, T; Kaji, Y; Nanbu, PN; Okamoto, F; Oshika, T; Wakabayashi, T, 2007) |
| "To investigate the relative pathogenicity of Candida albicans treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis." | 3.73 | Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. ( Duhamel, GE; Hoerrmann, N; Hornby, JM; Navarathna, DH; Nickerson, KW; Parkhurst, AM, 2005) |
| "To evaluate the therapeutic potential of FX0685, a new triazole antifungal agent, for the treatment of opportunistic fungal infections, particularly systemic candidiasis and aspergillosis, in vitro and in vivo studies were performed using fluconazole (FLC), itraconazole (ITC) and/or amphotericin B (AMB) as reference drugs." | 3.73 | In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans. ( Hoshiko, S; Ohtsuka, K; Okutomi, T; Takahata, S; Uchida, K; Yamaguchi, H, 2005) |
| ", with that of amphotericin B and fluconazole in a temporarily immunocompromised murine model of disseminated candidiasis." | 3.73 | Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. ( Denning, DW; Morrissey, G; Sharp, A; Warn, PA, 2005) |
| "Rats in Fp groups were given fluconazole in doses of 0 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg by gavage 30 min before induction of peritonitis." | 3.72 | Fluconazole attenuates lung injury and mortality in a rat peritonitis model. ( Arshaduddin, M; Evans, DP; Jacobs, S; Khan, HA; Moutaery, AA; Tariq, M, 2003) |
| "To determine the most efficient time point and concentration of topical corticosteroids in Candida albicans keratitis treated with fluconazole." | 3.72 | Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. ( Behrens-Baumann, W; König, W; Olbrisch, A; Schreiber, W; Vorwerk, CK, 2003) |
| "The aim of this investigation was to create a reproducible experimental model of disseminated Aspergillus flavus aspergillosis, and to compare the relative therapeutic efficacies of itraconazole and fluconazole in this model." | 3.72 | Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy. ( Geraldine, P; Kaliamurthy, J; Thomas, PA, 2003) |
| "The time of initiation of fluconazole treatment with or without dexamethasone, and the impact on mycological outcome and drug pharmacokinetics were assessed in a murine model of disseminated cryptococcosis." | 3.70 | Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. ( Dromer, F; Dupont, B; Improvisi, L; Lortholary, O; Nicolas, M; Petitjean, O; Ronin, O; Soreda, S; Tod, M, 1999) |
| "We determined the pharmacodynamic parameter and the magnitude of that parameter that was predictive of the efficacy of fluconazole in the treatment of disseminated candidiasis." | 3.70 | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. ( Andes, D; van Ogtrop, M, 1999) |
| "The present studies were performed to determine whether any beneficial interaction results from combination therapy with recombinant human granulocyte colony-stimulating factor (GCSF) and fluconazole in disseminated candidiasis in mice." | 3.69 | Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. ( Bocanegra, R; Graybill, JR; Luther, M, 1995) |
| "The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis." | 3.68 | Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. ( Hector, RF; Yee, E, 1990) |
| "The efficacy of fluconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis." | 3.68 | The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. ( Andriole, VT; George, D; Miniter, P; Patterson, TF, 1991) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 3.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "Voriconazole is a second-generation triazole antifungal agent, structurally derived from fluconazole with an extended spectrum of activity against a wide variety of yeasts and moulds." | 2.43 | Voriconazole: review of a broad spectrum triazole antifungal agent. ( Kofla, G; Ruhnke, M, 2005) |
| "Vulvovaginal candidiasis is a fungal infection for which we search for alternatives for its treatment." | 1.91 | Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model. ( Alves, SF; Amaral, AC; Costa, AF; da Silva, JT; Dantas de Sousa, PH; de Menezes, LB; Pellegrini, F, 2023) |
| "This study showed that a 10-day treatment with 20 mg/kg of fluconazole combined with sulfadiazine and pyrimethamine 1." | 1.62 | Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine. ( Anita, M; Hadi, M; Mohammad, JM; Reza, S; Sina, S; Soudabeh, E, 2021) |
| "In the present study, we assessed the adjunct effect of vitamin D3 in combination with Fluconazole (FLZ) against Vulvovaginal Candidiasis (VVC) in mice." | 1.62 | Prophylactic and Therapeutic Role of Vitamin D3 in Combination with Fluconazole Against Vaginal Candidiasis in a Murine Model. ( Allemailem, KS, 2021) |
| "Cryptococcosis is a common opportunistic infection in patients with advanced HIV infection and may also affect immunocompetent patients." | 1.56 | Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis. ( da Silva de Bastiani, FWM; de Azevedo Melo, AS; de Castro Spadari, C; Ishida, K; Pisani, PBB, 2020) |
| "Fluconazole promotes collecting duct AQP2 plasma membrane localization in the absence of AVP." | 1.51 | Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking. ( Ahlborn, R; Baltzer, S; Bleich, M; Compton, F; Dema, A; Eichhorst, J; Himmerkus, N; Hinze, C; Klussmann, E; Quintanova, C; Schmidt-Ott, KM; Vukićević, T; Wiesner, B; Zühlke, K, 2019) |
| "Posaconazole was found to inhibit amoeba growth within the first 12 hours of exposure, which was faster than any currently used drug." | 1.51 | Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis. ( Colon, BL; Guy, RK; Kyle, DE; Rice, CA, 2019) |
| "The major adverse effect associated with systemic administration of Fluconazole (FLZ), is hepatic toxicity." | 1.51 | Vitamin B combination reduces fluconazole toxicity in Wistar rats. ( Al-Abbasi, FA; Anwar, F; Mushtaq, G; Sadath, S, 2019) |
| " As the Ost concentration-time curve showed, Ost-S100-NP can increase the plasma concentration and relative bioavailability of Ost compared with Ost-suspension by oral administration." | 1.48 | Antifungal activity of osthol in vitro and enhancement in vivo through Eudragit S100 nanocarriers. ( Cao, YB; Gu, LQ; Han, B; Jiang, YY; Li, LP; Shen, CY; Wang, XJ; Yang, QL; Yu, YQ; Zhang, JY; Zhang, LL, 2018) |
| "Cryptococcosis is an invasive infection caused by yeast-like fungus of the genera Cryptococcus spp." | 1.46 | A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression. ( Abrahão, JS; Barcellos, VA; Bretas Oliveira, D; Carneiro, HC; Fontes, AC; Oliveira, LV; Paixão, TA; Resende-Stoianoff, MA; Ribeiro, NQ; Santos, DA; Santos, JR; Vainstein, MH, 2017) |
| "Bacterial pneumonia is a common cause of death worldwide." | 1.46 | Pulmonary delivery of tea tree oil-β-cyclodextrin inclusion complexes for the treatment of fungal and bacterial pneumonia. ( Du, L; Jin, Y; Li, M; Liu, B; Zhang, T; Zhu, L, 2017) |
| " The in vivo efficacy of this drug combination was evaluated using a Galleria mellonella model by determining survival rate, fungal burden and histological damage." | 1.46 | Strong synergism of dexamethasone in combination with fluconazole against resistant Candida albicans mediated by inhibiting drug efflux and reducing virulence. ( Huang, X; Li, X; Sun, S; Sun, W; Wang, D; Yu, C, 2017) |
| "Quercetin (QCT) is a dietary flavonoid and has been demonstrated to be antifungal against C." | 1.43 | Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. ( Gao, M; Wang, H; Zhu, L, 2016) |
| " Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent." | 1.43 | The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( Bozó, A; Domán, M; Kardos, G; Kovács, R; Majoros, L; Varga, I, 2016) |
| "Although guidelines for the treatment of invasive candidiasis have been published, no specific recommendations against C." | 1.43 | Antifungal therapies in murine infections by Candida kefyr. ( Capilla, J; Guarro, J; Martin-Vicente, A; Sanchis, M, 2016) |
| "Ellagic acid (EA) has been shown to have antioxidant, antibacterial, and anti-inflammatory activities." | 1.42 | Antifungal Activity of Ellagic Acid In Vitro and In Vivo. ( Aibai, S; Dawuti, G; Guo, X; Li, ZJ, 2015) |
| "Although the mechanisms responsible for acute liver failure (ALF) have not yet been fully elucidated, studies have indicated that intrahepatic macrophage activation plays an important role in the pathogenesis of ALF through intrahepatic microcirculatory disorder and consequent parenchymal cell death." | 1.40 | Intrahepatic microcirculatory disorder, parenchymal hypoxia and NOX4 upregulation result in zonal differences in hepatocyte apoptosis following lipopolysaccharide- and D-galactosamine-induced acute liver failure in rats. ( Enjoji, M; Kato, M; Kotoh, K; Masaki, Y; Miyazaki, M; Nakamuta, M; Takayanagi, R; Tanaka, K; Tanaka, M, 2014) |
| " Fluconazole may be an inferior agent for induction therapy because many patients cannot achieve the pharmacodynamic target." | 1.39 | Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. ( Al-Nakeeb, Z; Felton, TW; Goodwin, J; Gregson, L; Harrison, TS; Hope, WW; Howard, SJ; Livermore, J; Perfect, JR; Sharp, A; Sudan, A; Warn, PA, 2013) |
| "Fluconazole is an important antifungal triazole used against others CNS related opportunistic pathogens such as Cryptococcus neoformans and Candida spp." | 1.39 | Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. ( de Souza, W; Martins-Duarte, ÉS; Vommaro, RC, 2013) |
| "For treatment, fluconazole or posaconazole (10 mg/kg orally twice daily) was initiated 24 h post-inoculation." | 1.38 | A murine model of Cryptococcus gattii meningoencephalitis. ( Bocanegra, R; Graybill, JR; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Thompson, GR; Wiederhold, NP, 2012) |
| "Voriconazole was not as effective alone, but in combination with amphotericin B, it prolonged survival for the second-longest time period and provided the lowest colonization of target organs by the fungus." | 1.37 | Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. ( Chang, MR; Dias, AL; Gambale, V; Paula, CR; Prates, RA; Ribeiro, MS; Ruiz, Lda S; Silva, EG, 2011) |
| "As compared with those treated with FCZ alone, QHG combined with FCZ can raise the survival rate of the immuno-suppressed mice with systemic CA infection." | 1.35 | [Effect of qishen huoxue granule combined with fluconazole on survival rate of mice with systemic C. albaicans infection]. ( Li, SR; Wang, H; Zhang, SW, 2008) |
| "We developed a guinea pig model of cryptococcal meningitis to evaluate antifungal agents." | 1.34 | New guinea pig model of Cryptococcal meningitis. ( Bocanegra, R; Graybill, JR; Kirkpatrick, WR; Najvar, LK; Patterson, TF, 2007) |
| "Present-day methods of successful treatment of inflammatory bowel diseases (IBD) result from a better understanding of their pathophysiology due to advances in preclinical studies in this area of knowledge." | 1.34 | [Studies on the influence of Candida fungal colonization on the healing process of inflammatory lesions in the colon in rat animal model]. ( Brzozowski, T; Budak, A; Drozdowicz, D; Konturek, SJ; Kwiecień, S; Mach, T; Pawlik, WW; Rudnicka-Sosin, L; Sliwowski, Z; Targosz, A; Trojanowska, D; Zwolińska-Wcisło, M, 2007) |
| "In the present study on animal model of ulcerative colitis the influence of fungal colonization on the severity of inflammatory lesions in the colon and the course of their healing was evaluated." | 1.34 | [Candidiasis in the experimental model of ulcerative colitis]. ( Brzozowski, T; Budak, A; Drozdowicz, D; Konturek, SJ; Kwiecień, S; Mach, T; Mazurkiewicz-Janik, M; Pawlik, WW; Rudnicka-Sosin, L; Sliwowski, Z; Trojanowska, D; Zwolińska-Wcisło, M, 2007) |
| " Regression analysis was used to assess the correspondence between the in vitro fluconazole concentration-response curve and the murine dose-response curve observed in our previously reported murine model." | 1.33 | Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. ( Bauer, M; Citron, D; Harrison, TS; Larsen, RA; Rathbun, M; Sanchez, A; Thomas, AM, 2005) |
| "Fluconazole has been effective against Candida albicans in various animal models." | 1.33 | Retinal toxicity of intravitreally injected plain and liposome formulation of fluconazole in rabbit eye. ( Gupta, SK; Nag, TC; Narayanan, K; Ravi, AK; Velpandian, T, 2006) |
| "Fluconazole alone was not found significantly effective against C." | 1.32 | Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004) |
| "In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles." | 1.32 | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. ( Andes, D; Conklin, R; Marchillo, K; Stamstad, T, 2003) |
| "Treatment with fluconazole at 10 mg/kg of body weight/day for 12 weeks not only reduced the numbers of viable organisms within the chambers compared to those in untreated mice (mean +/- standard deviation of log(10) CFU of 0." | 1.31 | Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice. ( Hahn, BL; Sohnle, PG, 2002) |
| "75 mg/kg), administered singly or in combination with flucytosine (100 mg/kg)." | 1.31 | Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model. ( Ghannoum, MA; Hossain, MA; Long, L; Mukherjee, PK; Reyes, G, 2002) |
| " The level of resistance to fungal infections was superior to that given by fluconazole (FLC) treatment alone and highly enhanced by the combination with FLC." | 1.31 | Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections. ( Endo, M; Ino-Ue, T; Kato, I; Kurasawa, M; Mizutani, S; Saito, H; Takesako, K; Uno, Y, 2000) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 1.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| " Overall, fluconazole had dose-responsive efficacy, whereas neither G-CSF nor IFN-gamma alone or in combination with fluconazole improved efficacy." | 1.31 | Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. ( Clemons, KV; Stevens, DA, 2000) |
| "After Trichophyton mentagrophytes infections had been established in the test animals, the antifungal agents were administered once per day for 14 days." | 1.31 | Comparison of the therapeutic efficacy of oral doses of fluconazole and itraconazole in a guinea pig model of dermatophytosis. ( Nagino, K; Ogawa, M; Shimohira, H; Uchida, K; Yamaguchi, H, 2000) |
| "Fluconazole was less effective as a single agent than was amphotericin B, despite the greater penetration of fluconazole into brain tissues." | 1.31 | Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. ( Brizendine, E; Connolly, PA; Durkin, MM; Haynes, RR; LeMonte, AM; Smedema, ML; Wheat, LJ, 2002) |
| "Voriconazole (UK-109,496) is a new triazole with in vitro activity against a wide spectrum of fungi including yeasts intrinsically resistant to fluconazole such as Candida krusei." | 1.30 | Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. ( Bhat, N; Ghannoum, MA; Okogbule-Wonodi, I; Sanati, H, 1999) |
| " Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of fluconazole as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of fluconazole was significantly more efficacious than a lower dose [P < 0." | 1.30 | Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. ( Graybill, JR; Najvar, LK; Nguyen, MH; Yu, CY, 1997) |
| "Treatment with fluconazole, amphotericin B, or a combination of both significantly prolonged survival of animals lethally challenged with Aspergillus fumigatus." | 1.29 | Combination therapy in experimental invasive aspergillosis. ( Andriole, VT; George, D; Kordick, D; Miniter, P; Patterson, TF, 1993) |
| "Fluconazole is an orally active bis-triazole antifungal agent that acts by selective inhibition of lanosterol 14 alpha-demethylase, a key enzyme for maintenance of the fungal cell wall." | 1.29 | Human carcinogenic risk assessment based on hormonal effects in a carcinogenicity study in rats with the antifungal agent, fluconazole. ( Longeart, L; Monro, AM; Paulus, G, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.55) | 18.7374 |
| 1990's | 27 (14.92) | 18.2507 |
| 2000's | 59 (32.60) | 29.6817 |
| 2010's | 77 (42.54) | 24.3611 |
| 2020's | 17 (9.39) | 2.80 |
| Authors | Studies |
|---|---|
| Fujie, A | 1 |
| Iwamoto, T | 1 |
| Sato, B | 1 |
| Muramatsu, H | 1 |
| Kasahara, C | 1 |
| Furuta, T | 1 |
| Hori, Y | 1 |
| Hino, M | 1 |
| Hashimoto, S | 1 |
| Ebiike, H | 2 |
| Masubuchi, M | 2 |
| Liu, P | 1 |
| Kawasaki, K | 2 |
| Morikami, K | 2 |
| Sogabe, S | 2 |
| Hayase, M | 2 |
| Fujii, T | 2 |
| Sakata, K | 2 |
| Shindoh, H | 2 |
| Shiratori, Y | 2 |
| Aoki, Y | 2 |
| Ohtsuka, T | 2 |
| Shimma, N | 2 |
| Aoyama, T | 1 |
| Niizuma, S | 1 |
| Park, JS | 1 |
| Yu, KA | 1 |
| Kang, TH | 1 |
| Kim, S | 1 |
| Suh, YG | 1 |
| Serena, C | 3 |
| Rodríguez, MM | 1 |
| Mariné, M | 4 |
| Pastor, FJ | 4 |
| Guarro, J | 6 |
| Kirkpatrick, WR | 4 |
| Najvar, LK | 5 |
| Bocanegra, R | 5 |
| Patterson, TF | 7 |
| Graybill, JR | 6 |
| Kakeya, H | 2 |
| Miyazaki, Y | 1 |
| Senda, H | 1 |
| Kobayashi, T | 1 |
| Seki, M | 1 |
| Izumikawa, K | 2 |
| Yamamoto, Y | 2 |
| Yanagihara, K | 2 |
| Tashiro, T | 1 |
| Kohno, S | 2 |
| Ostrosky-Zeichner, L | 2 |
| Paetznick, VL | 3 |
| Rodriguez, J | 1 |
| Chen, E | 2 |
| Sheehan, DJ | 1 |
| MacCallum, DM | 1 |
| Coste, A | 1 |
| Ischer, F | 2 |
| Jacobsen, MD | 1 |
| Odds, FC | 1 |
| Sanglard, D | 5 |
| Bardiot, D | 1 |
| Thevissen, K | 1 |
| De Brucker, K | 1 |
| Peeters, A | 1 |
| Cos, P | 1 |
| Taborda, CP | 2 |
| McNaughton, M | 1 |
| Maes, L | 1 |
| Chaltin, P | 1 |
| Cammue, BP | 1 |
| Marchand, A | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 2 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 2 |
| Xu, H | 1 |
| Yan, ZZ | 1 |
| Guo, MB | 1 |
| An, R | 1 |
| Wang, X | 1 |
| Zhang, R | 1 |
| Mou, YH | 1 |
| Hou, Z | 1 |
| Guo, C | 1 |
| Sheng, B | 1 |
| Chen, Y | 2 |
| Sun, L | 2 |
| Xu, P | 1 |
| Han, B | 2 |
| Li, X | 5 |
| Yin, J | 1 |
| Li, T | 1 |
| Guan, H | 1 |
| Chen, S | 1 |
| Wang, Q | 1 |
| Li, C | 1 |
| Li, S | 2 |
| Jiang, X | 1 |
| Wang, P | 1 |
| He, Q | 1 |
| Wang, Y | 5 |
| Xiao, W | 1 |
| Yang, H | 1 |
| Santana, DJ | 1 |
| O'Meara, TR | 1 |
| Czechowicz, P | 3 |
| Nowicka, J | 3 |
| Neubauer, D | 3 |
| Chodaczek, G | 3 |
| Krzyżek, P | 3 |
| Gościniak, G | 3 |
| Fakhim, H | 1 |
| Vaezi, A | 1 |
| Morovati, H | 1 |
| Bandegani, A | 1 |
| Abbasi, K | 1 |
| Emami, S | 1 |
| Nasiry, D | 1 |
| Hashemi, SM | 1 |
| Ahangarkani, F | 1 |
| Badali, H | 1 |
| da Silva, JT | 1 |
| Dantas de Sousa, PH | 1 |
| Costa, AF | 1 |
| de Menezes, LB | 1 |
| Alves, SF | 1 |
| Pellegrini, F | 1 |
| Amaral, AC | 1 |
| de Castro Spadari, C | 1 |
| da Silva de Bastiani, FWM | 1 |
| Pisani, PBB | 1 |
| de Azevedo Melo, AS | 1 |
| Ishida, K | 1 |
| Vanherp, L | 1 |
| Poelmans, J | 1 |
| Hillen, A | 1 |
| Janbon, G | 1 |
| Brock, M | 1 |
| Lagrou, K | 2 |
| Vande Velde, G | 1 |
| Himmelreich, U | 1 |
| Dalla Lana, DF | 1 |
| Kaminski, TFA | 1 |
| Lavorato, SN | 1 |
| Merkel, S | 1 |
| Zanette, RA | 1 |
| da Rosa, PD | 1 |
| Staudt, KJ | 1 |
| de Araújo, BV | 1 |
| da Costa, B | 1 |
| Quatrin, PM | 1 |
| Bazana, LCG | 1 |
| Ferreira, FA | 1 |
| Caurio, CFB | 1 |
| de Andrade, SF | 1 |
| Alves, RJ | 1 |
| Fuentefria, AM | 1 |
| do Nascimento Dias, J | 1 |
| de Souza Silva, C | 1 |
| de Araújo, AR | 1 |
| Souza, JMT | 1 |
| de Holanda Veloso Júnior, PH | 1 |
| Cabral, WF | 1 |
| da Glória da Silva, M | 1 |
| Eaton, P | 1 |
| de Souza de Almeida Leite, JR | 1 |
| Nicola, AM | 1 |
| Albuquerque, P | 1 |
| Silva-Pereira, I | 1 |
| Matsumoto, Y | 1 |
| Yamazaki, H | 1 |
| Yamasaki, Y | 1 |
| Tateyama, Y | 1 |
| Yamada, T | 1 |
| Sugita, T | 2 |
| Chen, SM | 1 |
| Zou, Z | 1 |
| Guo, SY | 1 |
| Hou, WT | 1 |
| Qiu, XR | 1 |
| Zhang, Y | 1 |
| Song, LJ | 1 |
| Hu, XY | 1 |
| Jiang, YY | 5 |
| Shen, H | 1 |
| An, MM | 2 |
| Allemailem, KS | 1 |
| Sina, S | 1 |
| Mohammad, JM | 1 |
| Reza, S | 1 |
| Anita, M | 1 |
| Soudabeh, E | 1 |
| Hadi, M | 1 |
| Menon, S | 1 |
| Vartak, R | 1 |
| Patel, K | 1 |
| Billack, B | 1 |
| Zhao, Y | 1 |
| Huang, X | 3 |
| Yu, C | 3 |
| Yang, Y | 1 |
| Sun, S | 3 |
| Ribeiro, NQ | 4 |
| Costa, MC | 2 |
| Magalhães, TFF | 1 |
| Carneiro, HCS | 1 |
| Oliveira, LV | 3 |
| Fontes, ACL | 1 |
| Santos, JRA | 2 |
| Ferreira, GF | 1 |
| Araujo, GRS | 1 |
| Alves, V | 1 |
| Frases, S | 1 |
| Paixão, TA | 3 |
| de Resende Stoianoff, MA | 1 |
| Santos, DA | 5 |
| Sun, W | 1 |
| Wang, D | 1 |
| Bastos, RW | 1 |
| Holanda, RA | 2 |
| Silva, LC | 1 |
| Queiroz, ER | 1 |
| Li, LP | 1 |
| Wang, XJ | 1 |
| Zhang, JY | 1 |
| Zhang, LL | 1 |
| Cao, YB | 3 |
| Gu, LQ | 1 |
| Yu, YQ | 1 |
| Yang, QL | 1 |
| Shen, CY | 1 |
| Li, M | 1 |
| Zhu, L | 2 |
| Zhang, T | 1 |
| Liu, B | 1 |
| Du, L | 1 |
| Jin, Y | 1 |
| Gu, W | 1 |
| Yu, Q | 1 |
| Liao, K | 1 |
| Hang, C | 1 |
| de Assis, DN | 1 |
| Araújo, RS | 1 |
| Fuscaldi, LL | 1 |
| Fernandes, SOA | 1 |
| Mosqueira, VCF | 1 |
| Cardoso, VN | 1 |
| de Sá, NP | 1 |
| de Paula, LFJ | 1 |
| Lopes, LFF | 1 |
| Cruz, LIB | 1 |
| Matos, TTS | 1 |
| Lino, CI | 1 |
| de Oliveira, RB | 1 |
| de Souza-Fagundes, EM | 1 |
| Fuchs, BB | 1 |
| Mylonakis, E | 2 |
| Johann, S | 1 |
| Shi, J | 1 |
| Gao, A | 1 |
| Zhu, K | 1 |
| Zhang, H | 1 |
| Astvad, KMT | 1 |
| Delarze, E | 2 |
| Hare, RK | 1 |
| Arendrup, MC | 1 |
| Esposito, E | 1 |
| Campolo, M | 1 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Filippone, A | 1 |
| Peritore, AF | 1 |
| Cuzzocrea, S | 1 |
| Colon, BL | 1 |
| Rice, CA | 1 |
| Guy, RK | 1 |
| Kyle, DE | 1 |
| Thompson, GR | 2 |
| Krois, CR | 1 |
| Affolter, VK | 1 |
| Everett, AD | 1 |
| Varjonen, EK | 1 |
| Sharon, VR | 1 |
| Singapuri, A | 1 |
| Dennis, M | 1 |
| McHardy, I | 1 |
| Yoo, HS | 1 |
| Fedor, DM | 1 |
| Wiederhold, NP | 6 |
| Aaron, PA | 1 |
| Gelli, A | 2 |
| Napoli, JL | 1 |
| White, SD | 1 |
| Viriyakosol, S | 1 |
| Kapoor, M | 1 |
| Okamoto, S | 1 |
| Covel, J | 1 |
| Soltow, QA | 1 |
| Trzoss, M | 1 |
| Shaw, KJ | 1 |
| Fierer, J | 1 |
| Hiengrach, P | 1 |
| Panpetch, W | 1 |
| Worasilchai, N | 1 |
| Chindamporn, A | 1 |
| Tumwasorn, S | 1 |
| Jaroonwitchawan, T | 1 |
| Wilantho, A | 1 |
| Chatthanathon, P | 1 |
| Somboonna, N | 1 |
| Leelahavanichkul, A | 1 |
| Al-Abbasi, FA | 1 |
| Sadath, S | 1 |
| Mushtaq, G | 1 |
| Anwar, F | 1 |
| Vukićević, T | 1 |
| Hinze, C | 1 |
| Baltzer, S | 1 |
| Himmerkus, N | 1 |
| Quintanova, C | 1 |
| Zühlke, K | 1 |
| Compton, F | 1 |
| Ahlborn, R | 1 |
| Dema, A | 1 |
| Eichhorst, J | 1 |
| Wiesner, B | 1 |
| Bleich, M | 1 |
| Schmidt-Ott, KM | 1 |
| Klussmann, E | 1 |
| Matveev, AL | 1 |
| Krylov, VB | 1 |
| Khlusevich, YA | 1 |
| Baykov, IK | 1 |
| Yashunsky, DV | 1 |
| Emelyanova, LA | 1 |
| Tsvetkov, YE | 1 |
| Karelin, AA | 1 |
| Bardashova, AV | 1 |
| Wong, SSW | 1 |
| Aimanianda, V | 1 |
| Latgé, JP | 1 |
| Tikunova, NV | 1 |
| Nifantiev, NE | 1 |
| Lu, Y | 1 |
| Zhou, Z | 1 |
| Mo, L | 1 |
| Guo, Q | 1 |
| Peng, X | 1 |
| Hu, T | 1 |
| Zhou, X | 1 |
| Ren, B | 1 |
| Xu, X | 1 |
| Sasai, D | 1 |
| Okubo, Y | 1 |
| Ishiwatari, T | 1 |
| Kaneko, T | 1 |
| Murayama, SY | 1 |
| Shimamura, T | 1 |
| Shinozaki, M | 1 |
| Hasegawa, C | 1 |
| Mitsuda, A | 1 |
| Tochigi, N | 1 |
| Wakayama, M | 1 |
| Nemoto, T | 1 |
| Shibuya, K | 1 |
| Sudan, A | 1 |
| Livermore, J | 1 |
| Howard, SJ | 1 |
| Al-Nakeeb, Z | 1 |
| Sharp, A | 2 |
| Goodwin, J | 1 |
| Gregson, L | 1 |
| Warn, PA | 2 |
| Felton, TW | 1 |
| Perfect, JR | 1 |
| Harrison, TS | 2 |
| Hope, WW | 1 |
| Li, DD | 1 |
| Deng, L | 1 |
| Hu, GH | 1 |
| Zhao, LX | 1 |
| Hu, DD | 1 |
| Tanaka, M | 1 |
| Tanaka, K | 1 |
| Masaki, Y | 1 |
| Miyazaki, M | 1 |
| Kato, M | 1 |
| Kotoh, K | 1 |
| Enjoji, M | 1 |
| Nakamuta, M | 1 |
| Takayanagi, R | 1 |
| Sandoval-Denis, M | 1 |
| Capilla, J | 3 |
| Sutton, DA | 2 |
| Fothergill, AW | 3 |
| Meulendyke, KA | 1 |
| Queen, SE | 1 |
| Engle, EL | 1 |
| Shirk, EN | 1 |
| Liu, J | 1 |
| Tarwater, PM | 1 |
| Graham, DR | 1 |
| Mankowski, JL | 1 |
| Zink, MC | 1 |
| Li, D | 2 |
| Xi, L | 1 |
| Kucharíková, S | 2 |
| Neirinck, B | 1 |
| Sharma, N | 1 |
| Vleugels, J | 1 |
| Van Dijck, P | 2 |
| Kong, EF | 1 |
| Peters, BM | 1 |
| Shirtliff, ME | 1 |
| Jabra-Rizk, MA | 1 |
| Kaur, R | 1 |
| Garg, T | 1 |
| Goyal, AK | 1 |
| Rath, G | 1 |
| Khan, MA | 2 |
| Aljarbou, AN | 1 |
| Khan, A | 1 |
| Younus, H | 1 |
| Hu, G | 1 |
| Caza, M | 1 |
| Cadieux, B | 1 |
| Bakkeren, E | 1 |
| Do, E | 1 |
| Jung, WH | 1 |
| Kronstad, JW | 1 |
| Bom, VL | 1 |
| de Castro, PA | 1 |
| Winkelstroter, LK | 1 |
| Ramalho, LN | 1 |
| Brown, NA | 1 |
| Goldman, GH | 1 |
| Gabrielli, E | 1 |
| Roselletti, E | 1 |
| Luciano, E | 1 |
| Sabbatini, S | 1 |
| Mosci, P | 1 |
| Pericolini, E | 1 |
| Li, ZJ | 1 |
| Guo, X | 1 |
| Dawuti, G | 1 |
| Aibai, S | 1 |
| Qiu, X | 1 |
| Zhang, F | 1 |
| Yang, X | 1 |
| Wu, N | 1 |
| Jiang, W | 1 |
| Liu, Y | 2 |
| Coste, AT | 1 |
| Shubitz, LF | 1 |
| Trinh, HT | 1 |
| Galgiani, JN | 1 |
| Lewis, ML | 1 |
| Barker, BM | 1 |
| Lewis, ER | 1 |
| Doyle, AL | 1 |
| Hoekstra, WJ | 1 |
| Schotzinger, RJ | 1 |
| Garvey, EP | 1 |
| Bellanger, AP | 1 |
| Albert, ND | 2 |
| Lewis, RE | 2 |
| Walsh, TJ | 5 |
| Kontoyiannis, DP | 2 |
| Wang, L | 1 |
| Wang, C | 1 |
| Mei, H | 1 |
| Shen, Y | 1 |
| Lv, G | 1 |
| Zeng, R | 1 |
| Zhan, P | 1 |
| Liu, W | 1 |
| Gerstein, AC | 1 |
| Fu, MS | 1 |
| Mukaremera, L | 1 |
| Li, Z | 1 |
| Ormerod, KL | 1 |
| Fraser, JA | 1 |
| Berman, J | 2 |
| Nielsen, K | 1 |
| Gonzalez, JM | 1 |
| Rodriguez, CA | 1 |
| Zuluaga, AF | 1 |
| Agudelo, M | 1 |
| Vesga, O | 1 |
| Ahmadi, MS | 1 |
| Lee, HH | 1 |
| Sanchez, DA | 1 |
| Friedman, AJ | 1 |
| Tar, MT | 1 |
| Davies, KP | 1 |
| Nosanchuk, JD | 1 |
| Martinez, LR | 1 |
| Sanchis, M | 1 |
| Martin-Vicente, A | 1 |
| Frommeyer, G | 1 |
| Fischer, C | 1 |
| Lange, PS | 1 |
| Leitz, P | 1 |
| Fehr, M | 1 |
| Bogossian, H | 1 |
| Milberg, P | 1 |
| Eckardt, L | 1 |
| Huang, W | 1 |
| Liao, G | 1 |
| Baker, GM | 1 |
| Lau, R | 1 |
| Paderu, P | 1 |
| Perlin, DS | 1 |
| Xue, C | 1 |
| Wang, J | 1 |
| Wang, G | 1 |
| Quan, X | 1 |
| Ruan, L | 1 |
| Ruan, Y | 1 |
| Liu, N | 1 |
| Zhang, C | 1 |
| Bai, R | 1 |
| Santos, JR | 2 |
| César, IC | 1 |
| Ramos, LH | 1 |
| Freitas, GJ | 1 |
| Pianetti, GA | 1 |
| Ben-Ami, R | 1 |
| Zimmerman, O | 1 |
| Finn, T | 1 |
| Amit, S | 1 |
| Novikov, A | 1 |
| Wertheimer, N | 1 |
| Lurie-Weinberger, M | 1 |
| Fontes, AC | 1 |
| Bretas Oliveira, D | 1 |
| Carneiro, HC | 1 |
| Barcellos, VA | 1 |
| Abrahão, JS | 1 |
| Resende-Stoianoff, MA | 1 |
| Vainstein, MH | 1 |
| Kadosh, D | 1 |
| Olivo, M | 1 |
| Koselny, K | 1 |
| Green, J | 1 |
| DiDone, L | 1 |
| Halterman, JP | 1 |
| Cushion, MT | 1 |
| Rappelye, C | 1 |
| Wellington, M | 1 |
| Krysan, DJ | 1 |
| Thomson, P | 1 |
| Mayayo, E | 1 |
| López-Fernández, L | 1 |
| Bozó, A | 1 |
| Domán, M | 1 |
| Majoros, L | 2 |
| Kardos, G | 2 |
| Varga, I | 1 |
| Kovács, R | 1 |
| Gao, M | 1 |
| Wang, H | 3 |
| Nishikawa, H | 1 |
| Fukuda, Y | 1 |
| Mitsuyama, J | 1 |
| Tashiro, M | 1 |
| Tanaka, A | 1 |
| Takazono, T | 1 |
| Saijo, T | 1 |
| Yamamoto, K | 1 |
| Nakamura, S | 1 |
| Imamura, Y | 1 |
| Miyazaki, T | 1 |
| Mukae, H | 1 |
| Zwolińska-Wcisło, M | 2 |
| Sliwowski, Z | 3 |
| Drozdowicz, D | 3 |
| Kwiecień, S | 3 |
| Mazurkiewicz-Janik, M | 1 |
| Trojanowska, D | 3 |
| Rudnicka-Sosin, L | 3 |
| Mach, T | 3 |
| Budak, A | 3 |
| Brzozowski, T | 3 |
| Konturek, SJ | 3 |
| Pawlik, WW | 3 |
| Wheeler, RT | 1 |
| Kombe, D | 1 |
| Agarwala, SD | 1 |
| Fink, GR | 1 |
| Li, SR | 1 |
| Zhang, SW | 1 |
| Yang, RY | 1 |
| Wang, WL | 1 |
| Ao, JH | 1 |
| Hao, ZF | 1 |
| Zhang, J | 1 |
| Wang, CM | 1 |
| Jia, XM | 2 |
| Jia, JH | 1 |
| Li, MB | 1 |
| Cao, YY | 1 |
| Gao, PH | 2 |
| Liao, WQ | 1 |
| Zwolinska-Wcislo, M | 1 |
| Odabasi, Z | 1 |
| Rodriguez, JR | 1 |
| Rex, JH | 2 |
| Leitz, GJ | 1 |
| Vu, K | 1 |
| Habib, FS | 1 |
| Fouad, EA | 1 |
| Abdel-Rhaman, MS | 1 |
| Fathalla, D | 1 |
| Xu, K | 1 |
| Liu, L | 1 |
| Tan, JP | 1 |
| Li, Y | 1 |
| Fan, W | 1 |
| Wei, Z | 1 |
| Sheng, J | 1 |
| Yang, YY | 1 |
| Li, L | 1 |
| Martins-Duarte, ES | 2 |
| Lemgruber, L | 1 |
| de Souza, W | 2 |
| Vommaro, RC | 2 |
| Krishnan-Natesan, S | 1 |
| Manavathu, EK | 1 |
| Cutright, JL | 1 |
| Chandrasekar, PH | 1 |
| Mendes, FE | 1 |
| Faria, ES | 1 |
| Alvarenga, DG | 1 |
| Pinto, MR | 1 |
| Soares, BM | 1 |
| Cisalpino, PS | 1 |
| Silva, EG | 1 |
| Paula, CR | 1 |
| Dias, AL | 1 |
| Chang, MR | 1 |
| Ruiz, Lda S | 1 |
| Gambale, V | 1 |
| Prates, RA | 1 |
| Ribeiro, MS | 1 |
| Khodavandi, A | 1 |
| Alizadeh, F | 1 |
| Harmal, NS | 1 |
| Sidik, SM | 1 |
| Othman, F | 1 |
| Sekawi, Z | 1 |
| Jahromi, MA | 1 |
| Ng, KP | 1 |
| Chong, PP | 1 |
| Ferrari, S | 1 |
| Sanguinetti, M | 1 |
| Torelli, R | 1 |
| Posteraro, B | 1 |
| Mauric, O | 1 |
| Thallinger, C | 1 |
| Kugler, SA | 1 |
| Joukhadar, SM | 1 |
| Kovar, FM | 1 |
| Konz, KH | 1 |
| Graninger, W | 1 |
| Joukhadar, C | 1 |
| Lee, JH | 1 |
| Jang, EC | 1 |
| Han, Y | 1 |
| Schulz, B | 1 |
| Weber, K | 1 |
| Schmidt, A | 1 |
| Borg-von Zepelin, M | 1 |
| Ruhnke, M | 2 |
| Hayama, K | 1 |
| Ishibashi, H | 3 |
| Ishijima, SA | 1 |
| Niimi, K | 1 |
| Tansho, S | 1 |
| Ono, Y | 1 |
| Monk, BC | 1 |
| Holmes, AR | 2 |
| Harding, DR | 1 |
| Cannon, RD | 1 |
| Abe, S | 3 |
| Szilágyi, J | 1 |
| Földi, R | 1 |
| Gesztelyi, R | 1 |
| Bayegan, S | 1 |
| Juhász, B | 1 |
| Nagao, J | 1 |
| Cho, T | 1 |
| Uno, J | 1 |
| Ueno, K | 1 |
| Imayoshi, R | 1 |
| Nakayama, H | 1 |
| Chibana, H | 1 |
| Kaminishi, H | 1 |
| Sohnle, PG | 1 |
| Hahn, BL | 1 |
| Hossain, MA | 1 |
| Mukherjee, PK | 1 |
| Reyes, G | 1 |
| Long, L | 1 |
| Ghannoum, MA | 3 |
| Schreiber, W | 1 |
| Olbrisch, A | 1 |
| Vorwerk, CK | 1 |
| König, W | 1 |
| Behrens-Baumann, W | 1 |
| Kaliamurthy, J | 1 |
| Geraldine, P | 1 |
| Thomas, PA | 1 |
| Takakura, N | 1 |
| Sato, Y | 1 |
| Oshima, H | 2 |
| Uchida, K | 4 |
| Yamaguchi, H | 5 |
| Andes, D | 2 |
| Marchillo, K | 1 |
| Stamstad, T | 1 |
| Conklin, R | 1 |
| Tariq, M | 1 |
| Moutaery, AA | 1 |
| Arshaduddin, M | 1 |
| Khan, HA | 2 |
| Evans, DP | 1 |
| Jacobs, S | 1 |
| Yoder, BA | 1 |
| Winter, V | 1 |
| Coalson, JJ | 1 |
| Jabeen, R | 1 |
| Mohammad, O | 1 |
| Marr, K | 1 |
| Kofla, G | 1 |
| Takahata, S | 1 |
| Okutomi, T | 1 |
| Ohtsuka, K | 1 |
| Hoshiko, S | 1 |
| Morrissey, G | 1 |
| Denning, DW | 1 |
| Larsen, RA | 2 |
| Bauer, M | 2 |
| Thomas, AM | 2 |
| Sanchez, A | 1 |
| Citron, D | 1 |
| Rathbun, M | 1 |
| Navarathna, DH | 1 |
| Hornby, JM | 1 |
| Hoerrmann, N | 1 |
| Parkhurst, AM | 1 |
| Duhamel, GE | 1 |
| Nickerson, KW | 1 |
| Zhang, JD | 1 |
| Xu, Z | 1 |
| Sun, HH | 1 |
| Yan, L | 1 |
| Chen, HS | 1 |
| Chamilos, G | 1 |
| Lionakis, MS | 1 |
| Lopez-Ribot, JL | 1 |
| Saville, SP | 1 |
| Halder, G | 1 |
| Goldman, DL | 1 |
| Davis, J | 1 |
| Bommarito, F | 1 |
| Shao, X | 1 |
| Casadevall, A | 1 |
| Velpandian, T | 1 |
| Narayanan, K | 1 |
| Nag, TC | 1 |
| Ravi, AK | 1 |
| Gupta, SK | 1 |
| Marimon, R | 1 |
| Tokimatsu, I | 1 |
| Kushima, H | 1 |
| Hashinaga, K | 1 |
| Umeki, K | 1 |
| Ohama, M | 1 |
| Ishii, H | 1 |
| Kishi, K | 1 |
| Hiramatsu, K | 1 |
| Kadota, J | 1 |
| Chun, CD | 1 |
| Liu, OW | 1 |
| Madhani, HD | 1 |
| Hu, W | 1 |
| Ninomiya, K | 1 |
| Maruyama, N | 1 |
| Hiraoka, T | 1 |
| Kaji, Y | 1 |
| Wakabayashi, T | 1 |
| Nanbu, PN | 1 |
| Okamoto, F | 1 |
| Oshika, T | 1 |
| González, GM | 1 |
| Robledo, E | 1 |
| Saldívar, D | 1 |
| González, G | 1 |
| Bosques, F | 1 |
| Garza, E | 1 |
| Targosz, A | 1 |
| Maki, K | 1 |
| Watabe, E | 1 |
| Iguchi, Y | 1 |
| Matsumoto, S | 1 |
| Ikeda, F | 1 |
| Tawara, S | 1 |
| Mutoh, S | 1 |
| Paulus, G | 1 |
| Longeart, L | 1 |
| Monro, AM | 1 |
| Fujita, H | 1 |
| Masuda, H | 1 |
| Nakajima, T | 1 |
| Nakae, T | 1 |
| Narita, Y | 1 |
| Yada, K | 1 |
| Watanabe, M | 1 |
| Kagitani, Y | 1 |
| Mieth, H | 1 |
| Leitner, I | 1 |
| Meingassner, JG | 1 |
| Velez, JD | 1 |
| Allendoerfer, R | 1 |
| Luther, M | 2 |
| Rinaldi, MG | 1 |
| George, D | 2 |
| Kordick, D | 1 |
| Miniter, P | 2 |
| Andriole, VT | 2 |
| Ponnuvel, KM | 1 |
| Rama, CP | 1 |
| Menon, T | 1 |
| Parmegiani, RM | 1 |
| Loebenberg, D | 1 |
| Cacciapuoti, A | 1 |
| Antonacci, B | 1 |
| Norris, C | 1 |
| Menzel, F | 1 |
| Moss, L | 1 |
| Yarosh-Tomaine, T | 1 |
| Hare, RS | 1 |
| Miller, GH | 1 |
| Flattery, AM | 1 |
| Abruzzo, GK | 1 |
| Gill, CJ | 1 |
| Smith, JG | 1 |
| Bartizal, K | 1 |
| Nguyen, MH | 1 |
| Yu, CY | 1 |
| Sanati, H | 2 |
| Ramos, CF | 1 |
| Bayer, AS | 1 |
| Ding, JC | 1 |
| Diamond, DM | 1 |
| Leal, MA | 1 |
| Johnson, D | 1 |
| Williams, BK | 1 |
| Najvar, L | 1 |
| Nelson, PW | 1 |
| Lozano-Chiu, M | 1 |
| Espinel-Ingroff, A | 1 |
| Anaissie, EJ | 1 |
| Okogbule-Wonodi, I | 1 |
| Bhat, N | 1 |
| Lortholary, O | 1 |
| Nicolas, M | 1 |
| Soreda, S | 1 |
| Improvisi, L | 1 |
| Ronin, O | 1 |
| Petitjean, O | 1 |
| Dupont, B | 1 |
| Tod, M | 1 |
| Dromer, F | 1 |
| van Ogtrop, M | 1 |
| Groll, AH | 1 |
| Petraitis, V | 1 |
| Petraitiene, R | 1 |
| Field-Ridley, A | 1 |
| Calendario, M | 1 |
| Bacher, J | 3 |
| Piscitelli, SC | 1 |
| Mizutani, S | 1 |
| Endo, M | 1 |
| Ino-Ue, T | 1 |
| Kurasawa, M | 1 |
| Uno, Y | 1 |
| Saito, H | 1 |
| Kato, I | 1 |
| Takesako, K | 1 |
| Nagino, K | 2 |
| Shimohira, H | 2 |
| Ogawa, M | 2 |
| Sorensen, KN | 2 |
| Sobel, RA | 2 |
| Clemons, KV | 4 |
| Pappagianis, D | 2 |
| Stevens, DA | 4 |
| Williams, PL | 2 |
| Gonzalez, CE | 1 |
| Piscitelli, S | 1 |
| Bacher, JD | 1 |
| Peter, J | 2 |
| Torres, R | 1 |
| Shetti, D | 1 |
| Katsov, V | 1 |
| Kligys, K | 1 |
| Lyman, CA | 1 |
| Sugar, AM | 1 |
| Liu, XP | 1 |
| Arthington-Skaggs, BA | 1 |
| Warnock, DW | 2 |
| Morrison, CJ | 1 |
| Barchiesi, F | 1 |
| Schimizzi, AM | 1 |
| Caselli, F | 1 |
| Novelli, A | 1 |
| Fallani, S | 1 |
| Giannini, D | 1 |
| Arzeni, D | 1 |
| Di Cesare, S | 1 |
| Di Francesco, LF | 1 |
| Fortuna, M | 1 |
| Giacometti, A | 1 |
| Carle, F | 1 |
| Mazzei, T | 1 |
| Scalise, G | 1 |
| Shrikhande, S | 1 |
| Friess, H | 1 |
| Issenegger, C | 1 |
| Martignoni, ME | 1 |
| Yong, H | 1 |
| Gloor, B | 1 |
| Yeates, R | 1 |
| Kleeff, J | 1 |
| Büchler, MW | 1 |
| Lutz, JE | 1 |
| Beninati, C | 1 |
| Oggioni, MR | 1 |
| Boccanera, M | 1 |
| Spinosa, MR | 1 |
| Maggi, T | 1 |
| Conti, S | 1 |
| Magliani, W | 1 |
| De Bernardis, F | 1 |
| Teti, G | 1 |
| Cassone, A | 1 |
| Pozzi, G | 1 |
| Polonelli, L | 1 |
| Marchetti, O | 1 |
| Entenza, JM | 1 |
| Bille, J | 1 |
| Glauser, MP | 1 |
| Moreillon, P | 1 |
| Calderon, L | 1 |
| Howell, KJ | 1 |
| Irani, PR | 1 |
| Ju, JY | 1 |
| Polhamus, C | 1 |
| Marr, KA | 1 |
| Holland, SM | 1 |
| Bennett, JE | 1 |
| Haynes, RR | 1 |
| Connolly, PA | 1 |
| Durkin, MM | 1 |
| LeMonte, AM | 1 |
| Smedema, ML | 1 |
| Brizendine, E | 1 |
| Wheat, LJ | 1 |
| O'Day, DM | 2 |
| Head, WS | 1 |
| Robinson, RD | 1 |
| Williams, TE | 1 |
| Gedde, S | 1 |
| Bava, AJ | 1 |
| Negroni, R | 1 |
| Anaissie, E | 1 |
| Gokaslan, A | 1 |
| Hachem, R | 1 |
| Rubin, R | 1 |
| Griffin, G | 1 |
| Robinson, R | 1 |
| Sobel, J | 1 |
| Bodey, G | 1 |
| Reynes, J | 1 |
| Mallie, M | 1 |
| Ravisse, P | 1 |
| Bastide, JM | 1 |
| Georgiev, VS | 1 |
| Aoki, S | 1 |
| Mechinaud, F | 1 |
| Lee, J | 1 |
| Rubin, M | 1 |
| Pizzo, PA | 2 |
| Hector, RF | 1 |
| Yee, E | 1 |
| Lee, JW | 1 |
| Lecciones, J | 1 |
| Kelly, P | 1 |
| Thomas, V | 1 |
| Smith, KJ | 1 |
| Kennedy, CT | 1 |
| Johnson, EM | 1 |
| Hopwood, V | 1 |
| Van Cutsem, J | 1 |
| Vanden Bossche, H | 1 |
3 reviews available for fluconazole and Disease Models, Animal
| Article | Year |
|---|---|
Combination antifungal therapy: where are we now, and where are we going?
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Azoles; Candidiasis; Caspofungin; Disease | 2004 |
Voriconazole: review of a broad spectrum triazole antifungal agent.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cryptococ | 2005 |
Treatment and developmental therapeutics in aspergillosis. 2. Azoles and other antifungal drugs.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Azoles; Clotrim | 1992 |
1 trial available for fluconazole and Disease Models, Animal
| Article | Year |
|---|---|
Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa.
Topics: Adolescent; Adult; Aged; Animals; Antifungal Agents; Candida albicans; Candidiasis; Colitis, Ulcerat | 2009 |
177 other studies available for fluconazole and Disease Models, Animal
| Article | Year |
|---|---|
FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Bronchogenic Cyst; Candida albicans; Candidiasis; | 2001 |
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2.
Topics: Acyltransferases; Animals; Antifungal Agents; Area Under Curve; Benzofurans; Candida albicans; Candi | 2002 |
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3.
Topics: Acyltransferases; Animals; Antifungal Agents; Benzofurans; Candida albicans; Disease Models, Animal; | 2003 |
Discovery of novel indazole-linked triazoles as antifungal agents.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillus; Candida; Disease Models, Animal; Inda | 2007 |
Combined therapies in a murine model of blastoschizomycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Colony Count, Microbial; Disease Models, Animal; Drug Sy | 2007 |
New guinea pig model of Cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Cerebrospinal Fluid; Colony Count, Microbial; Cryptococcus neoformans; D | 2007 |
Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis.
Topics: Animals; Antifungal Agents; Brain; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; | 2008 |
Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.
Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Disease Models, Anima | 2009 |
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
Topics: Animals; Antifungal Agents; Base Sequence; Candida albicans; Candidiasis; Disease Models, Animal; DN | 2010 |
2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.
Topics: Acetamides; Animals; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Dose-Response | 2015 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.
Topics: 14-alpha Demethylase Inhibitors; Animals; Antifungal Agents; Binding Sites; Biofilms; Candida; Candi | 2021 |
Antifungal Treatment Aggravates Sepsis through the Elimination of Intestinal Fungi.
Topics: Amphotericin B; Animals; Antifungal Agents; Disease Models, Animal; Dysbiosis; Feces; Fluconazole; F | 2021 |
Forward and reverse genetic dissection of morphogenesis identifies filament-competent Candida auris strains.
Topics: Animals; Antifungal Agents; Candida auris; Candidiasis; CRISPR-Cas Systems; Disease Models, Animal; | 2021 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
In-vivo efficiency of the novel azole compounds (ATTAF-1 and ATTAF-2) against systemic candidiasis in a murine model.
Topics: Animals; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Invasive; Disease Models, Animal; | 2023 |
Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Chitosan; Disease Models, A | 2023 |
Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Biofilms; Cryptococcosis; Cryptococcus gattii; Disease M | 2020 |
The Added Value of Longitudinal Imaging for Preclinical
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 2020 |
In vitro pharmacokinetics/pharmacodynamics modeling and efficacy against systemic candidiasis in Drosophila melanogaster of a bisaryloxypropanamine derivative.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Drosophila melano | 2021 |
Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against Candida albicans planktonic and biofilm cells.
Topics: Amphotericin B; Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Cell Membrane P | 2020 |
A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP.
Topics: Amphotericin B; Animals; Antifungal Agents; Bombyx; Disease Models, Animal; Fluconazole; Green Fluor | 2020 |
Preventing
Topics: Anidulafungin; Animals; Antibodies, Monoclonal; Antifungal Agents; Caco-2 Cells; Candida albicans; C | 2020 |
Prophylactic and Therapeutic Role of Vitamin D3 in Combination with Fluconazole Against Vaginal Candidiasis in a Murine Model.
Topics: Animals; Antifungal Agents; Candidiasis, Vulvovaginal; Cholecalciferol; Disease Models, Animal; Fema | 2021 |
Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Topics: 14-alpha Demethylase Inhibitors; Acute Disease; Animals; Antiprotozoal Agents; Brain; Disease Models | 2021 |
Evaluation of the antifungal activity of an ebselen-loaded nanoemulsion in a mouse model of vulvovaginal candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Disease Models, Animal; Emu | 2021 |
Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of
Topics: Ambroxol; Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Disease Models, Anima | 2017 |
Atorvastatin as a promising anticryptococcal agent.
Topics: Animals; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Cryptococcosis; Cryptococcus gat | 2017 |
Strong synergism of dexamethasone in combination with fluconazole against resistant Candida albicans mediated by inhibiting drug efflux and reducing virulence.
Topics: Animal Structures; Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbia | 2017 |
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcosis; Cryptococcus gattii; Disease Mode | 2017 |
Antifungal activity of osthol in vitro and enhancement in vivo through Eudragit S100 nanocarriers.
Topics: Administration, Oral; Animals; Antifungal Agents; Candida albicans; Candidiasis; Coumarins; Disease | 2018 |
Pulmonary delivery of tea tree oil-β-cyclodextrin inclusion complexes for the treatment of fungal and bacterial pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Antifungal Agents | 2017 |
In vivo activity of fluconazole/tetracycline combinations in Galleria mellonella with resistant Candida albicans infection.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, | 2018 |
Caffeic acid phenethyl ester synergistically enhances the antifungal activity of fluconazole against resistant Candida albicans.
Topics: Animals; Antifungal Agents; Caenorhabditis elegans; Caffeic Acids; Candida albicans; Candidiasis; Di | 2018 |
Biodistribution of free and encapsulated
Topics: Administration, Intravenous; Animals; Candida albicans; Candidiasis; Disease Models, Animal; Flucona | 2018 |
In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.
Topics: Animals; Antifungal Agents; Caenorhabditis elegans; Candida albicans; Candidiasis; Cyclohexanones; D | 2018 |
Tetrandrine enhances the antifungal activity of fluconazole in a murine model of disseminated candidiasis.
Topics: Animals; Antifungal Agents; Benzylisoquinolines; Candida albicans; Candidiasis; Disease Models, Anim | 2018 |
Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the
Topics: Animals; Antifungal Agents; Candida tropicalis; Candidiasis; Disease Models, Animal; Dose-Response R | 2018 |
Effect of pea protein plus grape seed dry extract on a murine model of Candida albicans induced vaginitis.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Disease Models, A | 2018 |
Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Azithromycin; Central Nervous System Protozoal Infect | 2019 |
Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort.
Topics: Alopecia Areata; Animals; Antifungal Agents; Disease Models, Animal; Fluconazole; Humans; Male; Mice | 2019 |
APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental
Topics: Aminopyridines; Amphotericin B; Animals; Antifungal Agents; Coccidioides; Disease Models, Animal; Fe | 2019 |
Administration of Candida Albicans to Dextran Sulfate Solution Treated Mice Causes Intestinal Dysbiosis, Emergence and Dissemination of Intestinal Pseudomonas Aeruginosa and Lethal Sepsis.
Topics: Animals; Candida albicans; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Fluconazole; Gastroin | 2020 |
Vitamin B combination reduces fluconazole toxicity in Wistar rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; | 2019 |
Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.
Topics: Analysis of Variance; Animals; Aquaporin 2; Biological Transport; Cell Membrane; Cells, Cultured; Co | 2019 |
Novel mouse monoclonal antibodies specifically recognizing β-(1→3)-D-glucan antigen.
Topics: Animals; Antibodies, Monoclonal; Antifungal Agents; Antigens, Fungal; Aspergillus fumigatus; beta-Gl | 2019 |
Fluphenazine antagonizes with fluconazole but synergizes with amphotericin B in the treatment of candidiasis.
Topics: Amphotericin B; Animal Structures; Animals; Antifungal Agents; Antipsychotic Agents; Candida albican | 2019 |
Histopathological evaluation of the efficacy of antifungals for experimental Trichosporon bloodstream infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Colony Count, Microbial; Disease Models, Animal; Flucona | 2013 |
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Topics: Animals; Antifungal Agents; Area Under Curve; Cryptococcus neoformans; Disease Models, Animal; Fluco | 2013 |
Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Disease Models, Animal; Fluconazole; F | 2013 |
Intrahepatic microcirculatory disorder, parenchymal hypoxia and NOX4 upregulation result in zonal differences in hepatocyte apoptosis following lipopolysaccharide- and D-galactosamine-induced acute liver failure in rats.
Topics: Aldehydes; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Fluconazole; Galactosamine; Hepato | 2014 |
In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbi | 2014 |
Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Amyloid beta-Protein Precursor; Animals; | 2014 |
Caenorhabditis elegans: a simple nematode infection model for Penicillium marneffei.
Topics: Amphotericin B; Animals; Antifungal Agents; Caenorhabditis elegans; Disease Models, Animal; Fluconaz | 2014 |
In vivo Candida glabrata biofilm development on foreign bodies in a rat subcutaneous model.
Topics: Animals; Antifungal Agents; Biofilms; Candida glabrata; Candidiasis; Disease Models, Animal; Echinoc | 2015 |
Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease.
Topics: Animals; Candida albicans; Candidiasis, Oral; Coinfection; Disease Models, Animal; Female; Fluconazo | 2015 |
Development, Optimization and Evaluation of Electrospun Nanofibers: Tool for Targeted Vaginal Delivery of Antimicrobials Against Urinary Tract Infections.
Topics: Adhesiveness; Administration, Intravaginal; Animals; Anti-Bacterial Agents; Calorimetry, Differentia | 2016 |
Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model.
Topics: Animals; Antifungal Agents; Benzoquinones; Candida albicans; Candidiasis; Disease Models, Animal; Dr | 2015 |
The endosomal sorting complex required for transport machinery influences haem uptake and capsule elaboration in Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Cyclic AMP-Dependent Protein Ki | 2015 |
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Disease Models, Animal; Drug Resistance, Fu | 2015 |
Comparison between bioluminescence imaging technique and CFU count for the study of oropharyngeal candidiasis in mice.
Topics: Animals; Candida albicans; Candidiasis, Oral; Colony-Forming Units Assay; Cortisone; Diagnostic Imag | 2015 |
Antifungal Activity of Ellagic Acid In Vitro and In Vivo.
Topics: Administration, Cutaneous; Animals; Antifungal Agents; Arthrodermataceae; Candida; Disease Models, A | 2015 |
Changes in the composition of intestinal fungi and their role in mice with dextran sulfate sodium-induced colitis.
Topics: Acute Disease; Animals; beta-Glucans; Colitis; Colon; Cytokines; Dextran Sulfate; Discriminant Analy | 2015 |
Adaptation of a Gaussia princeps Luciferase reporter system in Candida albicans for in vivo detection in the Galleria mellonella infection model.
Topics: Adaptation, Physiological; Animals; Candida albicans; Candidiasis; Copepoda; Disease Models, Animal; | 2015 |
Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.
Topics: 14-alpha Demethylase Inhibitors; Animals; Antifungal Agents; Coccidioides; Coccidioidomycosis; Disea | 2015 |
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Topics: Agar; Animals; Antifungal Agents; Culture Media; Disease Models, Animal; Drosophila melanogaster; Fe | 2015 |
Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection.
Topics: Animals; Antifungal Agents; Candida; Candidiasis, Oral; Candidiasis, Vulvovaginal; Colony Count, Mic | 2016 |
Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation.
Topics: Aneuploidy; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, Ani | 2015 |
Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Chromatography, High Pr | 2015 |
Sustained Nitric Oxide-Releasing Nanoparticles Induce Cell Death in Candida albicans Yeast and Hyphal Cells, Preventing Biofilm Formation In Vitro and in a Rodent Central Venous Catheter Model.
Topics: Animals; Antifungal Agents; Apoptosis; Biofilms; Candida albicans; Candidiasis; Catheter-Related Inf | 2016 |
Antifungal therapies in murine infections by Candida kefyr.
Topics: Amphotericin B; Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis, Invasive; Caspofungi | 2016 |
Divergent electrophysiologic profile of fluconazole and voriconazole in an experimental whole-heart model of proarrhythmia.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrophysiological Pheno | 2016 |
Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Caspofungin; Cell Membrane; Cryptococcosis; Cryptococcus neoformans; Dis | 2016 |
Fluconazole-induced long QT syndrome via impaired human ether-a-go-go-related gene (hERG) protein trafficking in rabbits.
Topics: Animals; Disease Models, Animal; Electrocardiography; ERG1 Potassium Channel; Female; Fluconazole; H | 2017 |
Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Chromatography, Liquid; Colony Count, Microbial; | 2016 |
Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.
Topics: Animals; Antifungal Agents; ATP-Binding Cassette Transporters; Biological Transport; Candida glabrat | 2016 |
A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus gattii; Disease Models, Animal; Female; Flu | 2017 |
Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Cyc | 2016 |
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Topics: Animals; Antifungal Agents; Candida; Caspofungin; Celecoxib; Cryptococcosis; Cryptococcus neoformans | 2016 |
Combined antifungal therapy against systemic murine infections by rare Cryptococcus species.
Topics: Administration, Intravenous; Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Crypt | 2017 |
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Disease Models, Animal; Drug Re | 2016 |
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
Topics: Animals; Antifungal Agents; Bacterial Adhesion; Biofilms; Candida albicans; Candidiasis, Vulvovagina | 2016 |
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Topics: Amidines; Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcosis; Cryptococcus gattii; Cr | 2017 |
[Candidiasis in the experimental model of ulcerative colitis].
Topics: Animals; Antifungal Agents; Candida; Candidiasis; Colitis, Ulcerative; Colon; Disease Models, Animal | 2007 |
Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment.
Topics: Animals; Antifungal Agents; beta-Glucans; Candida albicans; Candidiasis; Caspofungin; Cell Wall; Dis | 2008 |
[Effect of qishen huoxue granule combined with fluconazole on survival rate of mice with systemic C. albaicans infection].
Topics: Animals; Candida albicans; Candidiasis; Disease Models, Animal; Drug Therapy, Combination; Drugs, Ch | 2008 |
Pathogenicity of Trichosporon asahii in a murine model of disseminated trichosporonosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cyclophosphamide; Disease Models, Animal; Fluconazole; M | 2008 |
Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
Topics: Animals; Antifungal Agents; Antioxidants; Ascorbic Acid; Candida albicans; Candidiasis; Disease Mode | 2009 |
Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, | 2010 |
Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Topics: Animals; Antifungal Agents; Astemizole; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans | 2010 |
Liposomes as an ocular delivery system of fluconazole: in-vitro studies.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Corneal Stroma; Corneal Ulcer; Disease Mo | 2010 |
The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
Topics: Amino Acid Sequence; Amphotericin B; Animals; Antifungal Agents; Antimicrobial Cationic Peptides; Co | 2010 |
Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model.
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Disease Models, Animal; Dose-Response Relationship | 2010 |
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, | 2010 |
Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.
Topics: Animals; Antifungal Agents; Brain; Central Nervous System Fungal Infections; Cryptococcosis; Cryptoc | 2010 |
Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Colony Count, Microbial; Cryptococcosis; Cryptoco | 2011 |
Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model.
Topics: Animals; Candida albicans; Candidiasis; Disease Models, Animal; Disulfides; Female; Fluconazole; Hum | 2011 |
Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata.
Topics: Animals; Antifungal Agents; Azoles; Candida glabrata; Candidiasis; Colony Count, Microbial; Disease | 2011 |
The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats.
Topics: Animals; Antifungal Agents; Blood Proteins; Disease Models, Animal; Extracellular Space; Fluconazole | 2011 |
Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis.
Topics: Animals; Antibodies, Monoclonal; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Disease | 2011 |
Difference in virulence between fluconazole-susceptible and fluconazole-resistant Candida albicans in a mouse model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Cell Adhesion; Cell Line; Disease Models, | 2011 |
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.
Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Blood; Blood Chemical Analysis; Candida alb | 2012 |
A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model.
Topics: Animals; Candida albicans; Candidiasis, Oral; Disease Models, Animal; Drug Combinations; Drug Resist | 2012 |
A murine model of Cryptococcus gattii meningoencephalitis.
Topics: Animals; Antifungal Agents; Antigens, Fungal; Brain; Colony Count, Microbial; Cryptococcosis; Crypto | 2012 |
Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Caspofungin; Disease Models, Animal; Echinocand | 2012 |
Candida albicans Msi3p, a homolog of the Saccharomyces cerevisiae Sse1p of the Hsp70 family, is involved in cell growth and fluconazole tolerance.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Doxycycline; Drug | 2012 |
Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Topics: Acute Disease; Animals; Antifungal Agents; Antiprotozoal Agents; Cell Line; Cell Survival; Disease M | 2013 |
Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Diffusion Chambe | 2002 |
Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; | 2002 |
Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Conjunctivitis; Cornea; Disease Models, A | 2003 |
Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Brain; Colony C | 2003 |
A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis, Oral; Chlorpromazine; Dis | 2003 |
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Topics: Administration, Oral; Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; C | 2003 |
Fluconazole attenuates lung injury and mortality in a rat peritonitis model.
Topics: Adjuvants, Immunologic; Animals; Ascitic Fluid; Disease Models, Animal; Dose-Response Relationship, | 2003 |
Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model.
Topics: Animals; Animals, Newborn; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Drug Res | 2004 |
Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole.
Topics: Animals; Cell Line; Chloroquine; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Di | 2004 |
Effect of fluconazole on phagocytic response of polymorphonuclear leukocytes in a rat model of acute sepsis.
Topics: Analysis of Variance; Animals; Antifungal Agents; Disease Models, Animal; Dose-Response Relationship | 2005 |
In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Drug Evaluation, | 2005 |
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida tropicalis; Candidiasis; Cyclophosphamide; Disea | 2005 |
Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Cryptococcus neoformans; Disease Models, Animal; Dose-Response Relations | 2005 |
Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Farnesol; Flucona | 2005 |
In vitro and in vivo antifungal activities of the eight steroid saponins from Tribulus terrestris L. with potent activity against fluconazole-resistant fungal pathogens.
Topics: Animals; Antifungal Agents; Candida; Cryptococcus neoformans; Disease Models, Animal; Drug Resistanc | 2005 |
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species.
Topics: Animals; Antifungal Agents; Candida; Candidiasis; Colony Count, Microbial; Disease Models, Animal; D | 2006 |
Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma.
Topics: Animals; Antifungal Agents; Asthma; Bronchoalveolar Lavage Fluid; Chronic Disease; Cryptococcosis; C | 2006 |
Combined antifungal therapy in a murine infection by Candida glabrata.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida glabrata; Candidiasis; Colony Count, Microbial; | 2006 |
Retinal toxicity of intravitreally injected plain and liposome formulation of fluconazole in rabbit eye.
Topics: Animals; Antifungal Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Endophthalmiti | 2006 |
Effect of antifungal treatment in a murine model of blastoschizomycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Disease Models, Animal; Dose-Response Relationship, Drug | 2007 |
The prophylactic effectiveness of various antifungal agents against the progression of trichosporonosis fungemia to disseminated disease in a neutropenic mouse model.
Topics: Amphotericin B; Animal Structures; Animals; Antibiotic Prophylaxis; Antifungal Agents; Cyclophospham | 2007 |
A link between virulence and homeostatic responses to hypoxia during infection by the human fungal pathogen Cryptococcus neoformans.
Topics: Amino Acid Sequence; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Mo | 2007 |
A novel murine model of pharyngeal candidiasis with local symptoms characteristic of pharyngeal thrush produced by using an inhaled corticosteroid.
Topics: Administration, Inhalation; Animals; Antifungal Agents; Beclomethasone; Candida albicans; Candidiasi | 2007 |
Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits.
Topics: Animals; Antifungal Agents; Candidiasis; Conjunctiva; Disease Models, Animal; Echinocandins; Eye Inf | 2007 |
Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Colony Count, Microbial; Di | 2007 |
[Studies on the influence of Candida fungal colonization on the healing process of inflammatory lesions in the colon in rat animal model].
Topics: Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candidi | 2007 |
Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; F | 2007 |
Human carcinogenic risk assessment based on hormonal effects in a carcinogenicity study in rats with the antifungal agent, fluconazole.
Topics: Animals; Carcinogens; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluconazole; | 1994 |
[Protective effect of human macrophage colony-stimulating factor (hM-CSF) on fungal infection (1). In vivo effect of hM-CSF on systemic candidiasis and in vitro effect of hM-CSF on macrophages activities].
Topics: Animals; Candidiasis; Cells, Cultured; Disease Models, Animal; Fluconazole; Macrophage Colony-Stimul | 1995 |
The efficacy of orally applied terbinafine, itraconazole and fluconazole in models of experimental trichophytoses.
Topics: Administration, Oral; Animals; Antifungal Agents; Disease Models, Animal; Female; Fluconazole; Guine | 1994 |
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Animals; Disease Models, Animal; Drug Resistance, Microbial; Flu | 1993 |
Combination therapy in experimental invasive aspergillosis.
Topics: Amphotericin B; Animals; Antigens, Fungal; Aspergillosis; Disease Models, Animal; Drug Therapy, Comb | 1993 |
Systemic and gastrointestinal candidiasis of infant mice as model for antifungal therapy.
Topics: Amphotericin B; Animals; Candidiasis; Disease Models, Animal; Fluconazole; Flucytosine; Fungemia; Ga | 1993 |
Sch 39304, a new antifungal agent: oral and topical treatment of vaginal and superficial infections.
Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Candidiasis, Vulvovaginal | 1993 |
Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis.
Topics: Animals; Antifungal Agents; Candidiasis; Disease Models, Animal; Drug Interactions; Drug Therapy, Co | 1995 |
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antifungal Agents; Candida albicans; CD4-Pos | 1996 |
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; Dose-Response Re | 1997 |
Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; D | 1997 |
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Cryptococcus neoformans; Disease Models, Animal; Drug Evalu | 1997 |
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
Topics: Animals; Antifungal Agents; Candidiasis; Disease Models, Animal; Fluconazole; Kidney; Male; Mice; Mi | 1998 |
Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Drug Resis | 1999 |
Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.
Topics: Animals; Anti-Inflammatory Agents; Antifungal Agents; Biological Assay; Chromatography, High Pressur | 1999 |
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Colony Count, Microbial | 1999 |
Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Disease Models, Animal; Drug Carriers; Fluc | 1999 |
Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.
Topics: Animals; Antibodies, Monoclonal; Antifungal Agents; Antigens, Fungal; Candida albicans; Candidiasis; | 2000 |
Comparison of the therapeutic efficacy of oral doses of fluconazole and griseofulvin in a guinea pig model of dermatophytosis.
Topics: Administration, Oral; Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Female; Fl | 2000 |
Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis.
Topics: Animals; Antifungal Agents; Coccidioidomycosis; Disease Models, Animal; Fluconazole; Itraconazole; M | 2000 |
Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Animals; Candidiasis; Candidiasis, Oral; Child; Colony Count, Microbial; Disease Models, Animal; Dru | 2000 |
Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Antifungal Agents; Disease Models, Animal; Drug Therap | 2000 |
Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma.
Topics: Animals; Candida albicans; Candidiasis; Candidiasis, Oral; Disease Models, Animal; Drug Therapy, Com | 2000 |
Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Disease Models, Animal; Ergosterol; Femal | 2000 |
Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 2000 |
Fluconazole penetration into the pancreas.
Topics: Animals; Antifungal Agents; Disease Models, Animal; Fluconazole; Humans; Pancreatic Diseases; Pancre | 2000 |
Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Colony Count, Microbial; Cryptococcosis; Cryptoco | 2000 |
Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria.
Topics: Administration, Intravaginal; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agen | 2000 |
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Cyclosporine; Disease Models, Animal; Dru | 2000 |
Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model.
Topics: Animals; Antifungal Agents; Cerebrospinal Fluid; Coccidioides; Coccidioidomycosis; Colony-Forming Un | 2000 |
Comparison of the therapeutic efficacy of oral doses of fluconazole and itraconazole in a guinea pig model of dermatophytosis.
Topics: Administration, Oral; Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Female; Fl | 2000 |
Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Disease Models, Animal; Female; Fl | 2002 |
Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Central Nervous System Fungal Infections; Disease | 2002 |
The evaluation of therapeutic responses in experimental keratomycosis.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count | 1992 |
Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 1992 |
Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review.
Topics: Adult; Aged; Amphotericin B; Animals; Antifungal Agents; Child, Preschool; Disease Models, Animal; F | 1992 |
Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model.
Topics: AIDS-Related Opportunistic Infections; Animals; Candida albicans; Candidiasis; Candidiasis, Oral; Cr | 1992 |
The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis.
Topics: Animals; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Evaluation, Preclinical; | 1991 |
Orally administered antifungal therapy for experimental keratomycosis.
Topics: Administration, Oral; Animals; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; | 1990 |
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.
Topics: Acute Disease; Agranulocytosis; Amphotericin B; Animals; Candidiasis; Chronic Disease; Disease Model | 1990 |
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.
Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Crypto | 1990 |
SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.
Topics: Agranulocytosis; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans | 1990 |
Azole resistance in Candida albicans.
Topics: Adult; Animals; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis, Chronic Mucocutaneous | 1986 |